Insider Trading Activity For Brainstorm Cell Therapeutics (NASDAQ:BCLI)
June Sherie Almenoff , Director of Brainstorm Cell Therapeutics (NASDAQ:BCLI) reportedly Bought 5,700 shares of the company’s stock at an average price of 3.5 for a total transaction amount of $19,950.00 SEC Form
Insider Trading History For Brainstorm Cell Therapeutics (NASDAQ:BCLI)
On 4/28/2014 International Holdings Ltd Acc, Major Shareholder, bought 939,600 with an average share price of $0.30 per share and the total transaction amounting to $281,880.00.
On 6/13/2014 International Holdings Ltd Acc, Major Shareholder, bought 150,000 with an average share price of $0.35 per share and the total transaction amounting to $52,500.00.
On 6/16/2014 International Holdings Ltd Acc, Major Shareholder, bought 130,000 with an average share price of $0.29 per share and the total transaction amounting to $37,700.00.
On 9/15/2014 Anthony S Fiorino, CEO, bought 18,000 with an average share price of $0.28 per share and the total transaction amounting to $5,040.00.
On 9/22/2014 International Holdings Ltd Acc, Major Shareholder, bought 11,000 with an average share price of $4.17 per share and the total transaction amounting to $45,870.00.
On 10/1/2014 International Holdings Ltd Acc, Major Shareholder, bought 6,700 with an average share price of $4.14 per share and the total transaction amounting to $27,738.00.
On 10/10/2014 International Holdings Ltd Acc, Major Shareholder, bought 8,600 with an average share price of $4.06 per share and the total transaction amounting to $34,916.00.
Analyst Ratings History For Brainstorm Cell Therapeutics (NASDAQ:BCLI)
- On 3/8/2018 Maxim Group Set Price Target of rating Buy with a price target of $9.00
Recent Trading Activity for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Shares of Brainstorm Cell Therapeutics closed the previous trading session at 3.30 down -0.05 1.49% with 8113 shares trading hands.